Results 11 to 20 of about 57,488 (195)

PROGNOSIS IN IDH-MUTANT AND IDH-WILD TYPE GLIOBLASTOMA

open access: yesCumhuriyet Medical Journal, 2021
Glioblastoma (GBM) is the most common brain tumor in adults with a poor prognosis and predominantly astrocytic differentiation. GBM is classified according to the isocitrate dehydrogenase (IDH) mutation according to the World Health Organization (WHO) Brain Tumors 2016 classification.
KILIÇ, Eren   +6 more
openaire   +5 more sources

Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma

open access: yesCancer Cell
A subset of patients with IDH-mutant glioma respond to inhibitors of mutant IDH (IDHi), yet the molecular underpinnings of such responses are not understood. Here, we profiled by single-cell or single-nucleus RNA-sequencing three IDH-mutant oligodendrogliomas from patients who derived clinical benefit from IDHi. Importantly, the tissues were sampled on-
Avishay Spitzer   +29 more
openaire   +3 more sources

IDH inhibition in gliomas [PDF]

open access: yesNature Reviews Neurology
Gliomas are the most common malignant primary brain tumours in adults and cannot usually be cured with standard cancer treatments. Gliomas show intratumoural and intertumoural heterogeneity at the histological and molecular levels, and they frequently contain mutations in the isocitrate dehydrogenase 1 (IDH1) or IDH2 gene. IDH-mutant adult-type diffuse
Rudà, Roberta   +4 more
openaire   +2 more sources

Bringing IDH into the Fold [PDF]

open access: yesCancer Cell, 2016
Glioma-associated mutations in IDH1 or IDH2 lead to aberrant DNA methylation. A recent paper shows that loss of methylation-sensitive CTCF binding in IDH mutant cells leads to disruption of enhancer boundary function, which results in aberrant activation of PDGFRA expression via an enhancer associated with an adjacent gene.
Zadeh, Gelareh, Aldape, Kenneth
openaire   +2 more sources

Updates in IDH-Wildtype Glioblastoma

open access: yesNeurotherapeutics, 2022
Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed.
Jawad M. Melhem   +3 more
openaire   +2 more sources

FarmFit Insights Hub Analytics Code Repository

open access: yes, 2023
<h2>FarmFit Insights Hub Analytics</h2> <p><a href="https://farmfitinsightshub.org/">FarmFit Insights Hub</a> is a platform focused on understanding of how smallholder inclusive business models can deliver positive outcomes ...
Čengić, Mirza
core   +1 more source

Approaches to PET Imaging of Glioblastoma

open access: yesMolecules, 2020
Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approximately three in 100,000 adults annually. Positron emission tomography (PET) imaging provides an important non-invasive method of measuring biochemically specific targets
Lindsey R. Drake   +2 more
doaj   +1 more source

Mutant IDH in Gliomas: Role in Cancer and Treatment Options. [PDF]

open access: yes, 2023
Altered metabolism is a common feature of many cancers and, in some cases, is a consequence of mutation in metabolic genes, such as the ones involved in the TCA cycle.
Chiara Bardella   +3 more
core   +7 more sources

Indicadores socioeconómicos de desarrollo humano y desarrollo relativo al género en la sección municipal de Sabancuy, Carmen, Campeche

open access: yesRevista de Economía, 2010
El objetivo del presente estudio es conocer el grado de desarrollo que se ha alcanzado en la sección municipal de Sabancuy, localizada en el municipio del Carmen, Campeche, México, utilizando la metodología del programa de las Naciones Unidas para el ...
Ileana Mercedes Canepa Pérez   +1 more
doaj   +1 more source

The mechanisms of IDH mutations in tumorigenesis [PDF]

open access: yesCell Research, 2012
Tumor-associated mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes result in the loss of normal catalytic activity, the production of α-ketoglutarate (α-KG), and gain of a new activity, the production of an oncometabolite, R-2-hydroxylglutarate (R-2-HG).
Dan, Ye, Yue, Xiong, Kun-Liang, Guan
openaire   +2 more sources

Home - About - Disclaimer - Privacy